PCM
UTHR icon

Portolan Capital Management’s United Therapeutics UTHR Stock Holding History

Portolan Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6M Buy
63,435
+26,682
+73% +$13.3M 2% 11
2025
Q4 		$17.9M Buy
36,753
+18,677
+103% +$8.7M 0.96% 31
2025
Q3 		$7.58M Sell
18,076
-12,687
-41% -$4.27M 0.41% 71
2025
Q2 		$8.84M Sell
30,763
-14,305
-32% -$4.28M 0.55% 58
2025
Q1 		$13.9M Buy
45,068
+30,819
+216% +$10.6M 1.06% 34
2024
Q4 		$5.03M Sell
14,249
-16,257
-53% -$5.98M 0.34% 91
2024
Q3 		$10.9M Sell
30,506
-24,339
-44% -$8.22M 0.79% 43
2024
Q2 		$17.5M Sell
54,845
-56,077
-51% -$14.8M 1.44% 17
2024
Q1 		$25.5M Buy
110,922
+19,114
+21% +$4.31M 1.94% 12
2023
Q4 		$20.2M Buy
91,808
+10,760
+13% +$2.48M 1.77% 11
2023
Q3 		$18.3M Buy
81,048
+47,582
+142% +$11M 1.71% 12
2023
Q2 		$7.39M Sell
33,466
-44,282
-57% -$9.81M 0.65% 43
2023
Q1 		$17.4M Sell
77,748
-1,069
-1% -$264K 1.66% 13
2022
Q4 		$21.9M Sell
78,817
-2,473
-3% -$624K 2.17% 6
2022
Q3 		$17M Sell
81,290
-3,554
-4% -$795K 1.8% 13
2022
Q2 		$20M Buy
+84,844
New +$17.2M 2.01% 9
2020
Q3 		– Sell
-75,039
Closed -$9.08M – 155
2020
Q2 		$9.08M Sell
75,039
-39,738
-35% -$4.47M 1.04% 33
2020
Q1 		$10.9M Buy
+114,777
New +$10.9M 1.63% 17
2018
Q1 		– Sell
-34,227
Closed -$5.06M – 113
2017
Q4 		$5.06M Sell
34,227
-11,962
-26% -$1.52M 0.55% 67
2017
Q3 		$5.41M Buy
+46,189
New +$5.9M 0.65% 61
2017
Q2 		– Sell
-33,469
Closed -$4.53M – 136
2017
Q1 		$4.53M Sell
33,469
-47,447
-59% -$7.19M 0.59% 66
2016
Q4 		$11.6M Buy
80,916
+34,635
+75% +$4.42M 1.56% 15
2016
Q3 		$5.46M Sell
46,281
-70,320
-60% -$8.45M 0.75% 54
2016
Q2 		$12.3M Buy
116,601
+12,180
+12% +$1.36M 1.78% 13
2016
Q1 		$11.6M Buy
104,421
+75,466
+261% +$9.55M 1.56% 16
2015
Q4 		$4.54M Buy
+28,955
New +$4.22M 0.57% 70

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Portolan Capital Management's UTHR Position: Q1 2026 in Review

Portolan Capital Management increased its United Therapeutics (UTHR) stake by 73% in Q1 2026, buying an estimated $13.3M and bringing the position to 63,435 shares worth $37.6M. The position accounts for 2% of the portfolio, ranked #11.

Portolan Capital Management first reported a position in UTHR in Q4 2015 and has held it in 26 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Portolan Capital Management held 63,435 shares of United Therapeutics worth $37.6M as of Q1 2026.
  • Portolan Capital Management bought 26,682 United Therapeutics shares in Q1 2026, an estimated $13.3M.
  • United Therapeutics made up 2% of Portolan Capital Management's portfolio in Q1 2026, its #11 holding.
  • Portolan Capital Management first reported a position in United Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.